Author： Peest D. Deicher H. Coldewey R. Leo R. Bartl R. Bartels H. Braun H.J. Fett W. Fischer J.T. Gobel B. Harms P. Henke R. Hoffmann L. Kreuser E.D. Maier W.D. Meier C.R. Oertel J. Petit M. Planker M. Platzeck C. Respondek M. Schafer E. Schumacher K. Stennes M. Stenzinger W. Tirier C. Wagner H. Weh H.J. von Wussow P. Wysk J.
Publisher： Elsevier
ISSN： 0959-8049
Source： European Journal of Cancer, Vol.31, Iss.2, 1995-01, pp. : 146-151
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
Should alpha-interferon be included as standard treatment in multiple myeloma?
By Zulian G.B.
European Journal of Cancer, Vol. 34, Iss. 1, 1998-01 ,pp. :
Access to resources
Recommend
Should alpha-interferon be included as standard treatment in multiple myeloma?
By Browman G.P.
European Journal of Cancer, Vol. 34, Iss. 1, 1998-01 ,pp. :
Should alpha-interferon be included as standard treatment in multiple myeloma?
European Journal of Cancer, Vol. 34, Iss. 1, 1998-01 ,pp. :
How Does Interferon-Alpha Exert Its Antitumour Activity in Multiple Myeloma?
By Grandér Dan
Acta Oncologica, Vol. 39, Iss. 7, 2000-11 ,pp. :